Physical activity and benign prostatic hyperplasia

Archives of Internal Medicine

Volumn 158, Issue 21, 1998, Pages 2349-2356

  Platz, Elizabeth A ^a   Kawachi, Ichiro ^a,b   Rimm, Eric B ^a,b   Colditz, Graham A ^a,b   Stampfer, Meir J ^a,b   Willett, Walter C ^a,b   Giovannucci, Edward ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AGING; ARTICLE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RISK ASSESSMENT; SMOOTH MUSCLE TONE; WALKING;

EID: 0032561696     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.21.2349     Document Type: Article

References (34)

1. Bostwick DG. Pathology of benign prostatic hyperplasia. In: Kirby R, McConnell J, Fitzpatrick J, Roehrborn C, Boyle P, eds. Textbook of Benign Prostatic Hyperplasia. Oxford, England: ISIS Medical Media Ltd; 1996:91-104.
2. Garraway WM, Colins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet. 1991;338:469-471.
3. Graves EJ, Gillum BS. Detailed diagnoses and procedures, National Hospital Discharge Survey, 1994. Vital Health Stat 13. 1997;127:1-145.
4. Caine M. The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. J Urol. 1986;136:1-4.
5. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med. 1996;335:533-539.
6. Walsh PC. Treatment of benign prostatic hyperplasia. N Engl J Med. 1996;335: 586-587.
7. Braunwald E. Harrison's Principles of Internal Medicine. 11th ed. New York, NY: McGraw Hill Book Co; 1987:364.
8. Giovannucci E, Rimm EB, Chute CG, et al. Obesity and benign prostatic hyperplasia. Am J Epidemiol. 1994;140:989-1002.
9. Gann PH, Hennekens CH, Longcope C, Verhoek-Oftedahl W, Grodstein F, Stampfer MJ. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate. 1995;26:40-49.
10. Rimm EB, Stampfer MJ, Colditz GA, Chute CG, Litin LB, Willett WC. Validity of self-reported waist and hip circumferences in men and women. Epidemiology. 1990;1:466-473.
11. Barry MJ, Fowler FJ, Oleary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 1992;148:1549-1557.
12. Welch G, Kawachi I, Barry MJ, Giovannucci E, Colditz GA, Willett WC. Distinction between symptoms of voiding and filling in benign prostate hyperplasia: findings from the Health Professionals Follow-up Study. Urology. 1998;51:422-427.
13. Chasen-Taber S, Rimm EB, Stampfer MJ, et al. Reproducibility and validity of a self-administered physical activity questionnaire for male health professionals. Epidemiology. 1996;7:1-6.
14. Ainsworth BE, Haskell WL, Leon AS, et al. Compendium of physical activities: classification of energy costs of human physical activities. Med Sci Sports Exerc. 1993;25:71-80.
15. Girman CJ, Jacobsen SJ, Guess HA, et al. Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol. 1995;153:1510-1515.
16. Simpson RJ, Fisher W, Lee AJ, Russell EB, Garraway M. Benign prostatic hyperplasia in an unselected community-based population: a survey of urinary symptoms, bothersomeness and prostatic enlargement. Br J Urol. 1996;77:186-191.
17. Craigen AA, Hickling JB, Saunders CR, Carpenter RG. Natural history of prostatic obstruction: a prospective survey. J R Coll Gen Pract. 1969;18:226-232.
18. Clarke R. The prostate and the endocrines: a control series. Br J Urol. 1937;9: 254-271.
19. 1c subtype. Mol Pharmacol. 1994;45:703-708.
20. 1c-) adrenoceptor subtype. Br J Pharmacol. 1995;115:781-786.
21. Hedlund H, Andersson KE, Larsson B. Alpha-adrenoceptors and muscarinic receptors in the isolated human prostate. J Urol. 1985;134:1291-1298.
22. Chapple CR, Aubrey ML, James S, et al. Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localisation. Br J Urol. 1989;63:487-496.
23. Shapiro E, Becich MJ, Hartanto V, Lepor H. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostatic hyperplasia. J Urol. 1992;147:1293-1297.
24. Ishigooka M, Hashimoto T, Hayami S, Suzuki Y, Sasagawa I, Nakada T. Correlation between morphometric differences and norepinephrine content in benign prostatic hyperplasia. Prostate. 1996;28:385-391.
25. Kitada S, Kumazawa J. Pharmacological characteristics of smooth muscle in benign prostatic hyperplasia and normal prostatic tissue. J Urol. 1987;138:158-160.
26. Shapiro E, Hartanto V, Lepor H. The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate. 1992;21:297-307.
27. Kyprianou N, Davies P. Association states of androgen receptors in nuclei of human benign hypertrophic prostate. Prostate. 1986;8:363-380.
28. Frydenberg M, Foo TM, Jones AS, et al. Benign prostatic hyperplasia: video image analysis and its relationship to androgen and epidermal growth factor receptor expression. J Urol. 1991;146:872-876.
29. Peters CA, Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med. 1987; 317:599-604.
30. Wilson JD. The pathogenesis of benign prostatic hyperplasia. Am J Med. 1980; 68:745-756.
31. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science. 1974;186:1213-1215.
32. Andersson S, Berman DM, Jenkins EP, Russell DW. Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism. Nature. 1991;354:159-161.
33. Hackney AC. The male reproductive system and endurance exercise. Med Sci Sports Exerc. 1996;28:180-189.
34. Wheeler GD, Wall SR, Belcastro AN, Cumming DC. Reduced serum testosterone and prolactin levels in male distance runners. JAMA 1984;252:514-516.